An Unusual Skin Adverse Event after Switching from Intravenous to Subcutaneous VEDOLIZUMAB Therapy in Patients with Ulcerative Colitis. acmcr [Internet]. 2023 Feb. 10 [cited 2026 Sep. 11];7(1):77-9. Available from: https://fortunejournals.org/ojs/index.php/acmcr/article/view/22706